A Phase 1, Open-Label, Exploratory, Fixed-Sequence, Pharmacokinetic Single Dose Study of IVL3004 Versus Vivitrol (Naltrexone) Long-Acting Injectable (LAI) and IVL4002 in Healthy Subjects
Latest Information Update: 21 Oct 2024
At a glance
Most Recent Events
- 11 Oct 2024 Status changed from not yet recruiting to recruiting.
- 14 Aug 2024 Planned number of patients changed from 30 to 40.
- 14 Aug 2024 Planned End Date changed from 31 Mar 2024 to 6 May 2025.